Previous 10 | Next 10 |
Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to...
Alimera Sciences, Inc. (ALIM) Q2 2022 Earnings Conference Call July 27, 2022 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Cal...
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021 U.S. End User Demand up 45% vs. Second Quarter of 2021 International Segment End User Demand Up 21% vs. Second Quarter of 2021 ATLANTA, July 27, 2022 (GLOBE NEWSWIRE...
Alimera Sciences ( NASDAQ: ALIM ): Q2 For further details see: Alimera Sciences reports Q2 results
ADP , AEP , ALIM , ALKS , APH , ASC , ATOS , AVY , BA , OTCQX:BASFY , BG , BMY , BSX , BXMT , CAMT , CCJ , CHEF , CME , COOP , CPG , CS , CSTM , OTCQX:DANOY , DB , EDU , EQNR , EVR ...
ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will...
Alimera Sciences ( NASDAQ: ALIM ) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval...
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
ATLANTA, July 13, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...